Home

Mesothelioma

• About Mesothelioma
• Mesothelioma Cause
• Mesothelioma Symptoms
• Mesothelioma Diagnosis
• Mesothelioma Stages

Mesothelioma Treatment

• Treatment Options
• Mesothelioma Surgery
• Mesothelioma Chemotherapy
• Mesothelioma Radiation
• New Approaches
• Palliative Care

Mesothelioma Specialists

• Choosing Your Doctor
• Your Health Care Team
• Cancer Centers

Clinical Trials

• Trial Basics
• Eligibility
• Current Trials

Managing Your Care

• Your Personal Records
• Your Medications
• Your Expenses

Veterans Resources

• Veterans' Mesothelioma Home
• Asbestos Exposure
• Asbestos Diseases
• VA Health Care
• Veterans Service Officers

MESOTHELIOMA MEDICAL JOURNAL ARTICLES

Abstracts of recent articles about mesothelioma in medical journals. Abstracts on continuing mesothelioma research presented at a American Society of Clinical Oncology meeting held in Orlando, FL. Many of these are available through PubMed, a search engine of the National Library of Medicine. Overview of mesothelioma in PDF format. See our page on how to read medical abstracts.

1. Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature
2. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
3. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
4. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
5. Positron emission tomography predicts survival in malignant pleural mesothelioma.
6. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
7. Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab
8. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
9. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies.
10. Problems in mesothelioma diagnosis.
11. Therapeutic strategies for resectable malignant pleural mesothelioma
12. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
13. Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
14. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases
15. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
16. Second-line treatment for malignant pleural mesothelioma
17. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.
18. Genome-Wide PComparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.rofile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype
19. Fatal hemopericardial tamponade due to primary pericardial mesothelioma: a case report
20. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
21. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
22. Diagnosis and staging of pleural mesothelioma - English language abstract of a Japanese paper.
23. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
24. Malignant mesothelioma - Review from the Orphanet Journal of Rare Diseases
25. Malignant pleural mesothelioma: an update on biomarkers and treatment.
26. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
27. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
28. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma
29. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma
30. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients
31. Malignant pleural mesothelioma: computed tomography and correlation with histology.
32. "Mucin-positive" epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall.
33. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.
34. Malignant mesothelioma following treatment for Hodgkin's disease
35. Susceptibility and resistance in the genesis of asbestos-related mesothelioma
36. Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
37. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
38. Asbestos-related cancer risk in the presence of asbestosis or pleural plaques
39. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
40. Multidisciplinary treatment of malignant pleural mesothelioma.
41. An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers.
42. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.
43. Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence.
44. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.
45. Malignant pleural mesothelioma: Computed tomography and correlation with histology
46. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma
47. Fibrous morphology: a chief determinent of the biological fate of asbestos in the lungs
48. Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors.
49. Bevacizumab raises risk of clots in cancer patients
50. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
51. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
52. The mortality of women exposed environmentally and domestically to blue asbestos at Wittenoom, Western Australia.
53. Case study: Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
54. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
55. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
56. Recent advances in the treatment of malignant pleural mesothelioma.
57. Mapping the risk of mesothelioma due to neighborhood asbestos exposure.
58. Intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in malignant pleural mesothelioma
59. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
60. Extended surgical staging for potentially resectable malignant pleural mesothelioma.
61. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
62. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
63. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids.
64. Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with malignant pleural mesothelioma (MPM): Outcomes on Expanded Access Program (EAP).
65. Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP).
66. Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM).
67. A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).
68. Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1(dsFv)PE38 (SS1P).
69. Single dose electron beam radiation therapy for tumor wound seeding prophylaxis in mesothelioma.
70. Primary peritoneal mesothelioma: How aggressive should we be?
71. Cisplatin Plus Pemetrexed (Alimta) shows promise in treatment of Mesothelioma
72. Genetic predisposition and health effect of occupational exposure to asbestos.
73. The economic costs of health service treatments for asbestos-related mesothelioma deaths.
74. Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM).
75. A phase II trial of Tetrathiomolybdate [TM] after cytoreductive surgery for malignant pleural mesothelioma (MPM).
76. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
    
77. The role of Occupational Health and Safety Service in identifying past occupational exposure.
    
78. Early-life family structure and cancer risk.
    
79. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.
    
80. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
    
81. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
    

Proteomics and cancer research

Professionals dedicated to fighting advanced mesthelioma

News

• Mesothelioma News
• International News
• Pharmaceutical News
• Environmental News
• Medical Journal Articles

Resources

• Leading Cancer Links
• Financial Assistance, Compensation, and Legal Rights
• About Us
• Privacy Policy
• Disclaimer and Sponsorship Information

This site complies with the HONcode standard for trustworthy health information: verify here

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376